Another immunotherapeutic cohort of advanced/ metastatic melanoma patients (treated with anti-PD-1/ PD-L1 or anti-CTLA-4 agents) was also curated for validating the ICI predictive roles of the immune risk signature. This evidence concerns the gene CTLA4 and metastatic melanoma.